Share

July 2020; 7 (4) Clinical/Scientific NotesOpen Access

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients

Marieke van der Zwan, Dennis A. Hesselink, Esther Brusse, Pieter A. van Doorn, Martijn W.F. van den Hoogen, Annelies E. de Weerd, Bart C. Jacobs
First published April 16, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000721
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
560

Share

This article has a correction. Please see:

Article Information

vol. 7 no. 4 e721
DOI: 
https://doi.org/10.1212/NXI.0000000000000721
PubMed: 
32299841
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received November 25, 2019
  • Accepted in final form March 13, 2020
  • First Published April 16, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Marieke van der Zwan, MD,
    2. Dennis A. Hesselink, MD, PhD,
    3. Esther Brusse, MD, PhD,
    4. Pieter A. van Doorn, MD, PhD,
    5. Martijn W.F. van den Hoogen, MD, PhD,
    6. Annelies E. de Weerd, MD and
    7. Bart C. Jacobs, MD, PhD
  1. Marieke van der Zwan, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Netherlands journal of medicine, associate editor, from 2017 onwards

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Dennis A. Hesselink, MD, PhD,
    3. Scientific Advisory Boards:

    1. Scientific advisory board for Chiesi Pharma SpA.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honorariums from Astellas Pharma and Chiesi Pharma SpA.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Astellas Pharma.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Esther Brusse, MD, PhD,
    4. Scientific Advisory Boards:

    1. (1) I serves as an (unpaid)member of the Medical Advisory Board of the Dutch ADCA patient foundation (non- profit entity).

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Dutch ADCA patient foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Pieter A. van Doorn, MD, PhD,
    5. Scientific Advisory Boards:

    1. Advisory committee (GBS). Annexion. 2019 Advisory committee (GBS). Hansa Pharmaceuticals 2019 Advisory committee (CIDP). Argenx 2019 Advisory committee (CIDP). Octapharma. 2017, 2019

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. CSL honorarium symposium talk (2019)

    Editorial Boards:

    1. Journal of Neurological Sciences, Journal of Neuromuscular Diseases: member of editorial board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Research support investigator initiated trials: Sanguin Blood supply (SID-GBS study) Takeda (DRIP study)

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Martijn W.F. van den Hoogen, MD, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Astellas Pharma, funding for travel to conference 2. Amgen, funding for travel to conference 3. Sanofi, speaker honoraria 4. Vifor, speaker honoraria 5. Genzyme, funding for travel to conference 6. MSD, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Novartis 2. Shire

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Annelies E. de Weerd, MD and
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Bart C. Jacobs, MD, PhD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Funding for travel from Baxter International Inc for a scientific meeting.

    Editorial Boards:

    1. Journal of the Peripheral Nervous System, member of the editorial board, 2011 - 2018.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) unrestricted research funding, eSPIN Award 2013, Grifols (2) unrestricted research funding, 2014, CSL-Behring (3) Interlaken Leadership Award 2014, CSL-Behring (4) unrestricted research funding, 2014, Baxalta (5) unrestricted research funding, 2017/2019, Annexon (6) unrestricted research funding, 2019, Hansa Medical AB

    Research Support, Government Entities:

    1. Netherlands Organization for Health Research and Development

    Research Support, Academic Entities:

    1. (1) ZikaPLAN, Horizon 2020 (EU)

    Research Support, Foundations and Societies:

    1. (1) Erasmus MC grant, PI, 2007-2011 (2) Prinses Beatrix Prinses Beatrix Spierfonds (W.OR07- 27), PI, 2007-2009 (3) Prinses Beatrix Prinses Beatrix Spierfonds (W.OR07- 28), PI, 2007-2011 (4) GBS-CIDP Foundation International, PI, 2009 (5) GBS-CIDP Foundation International, PI, 2011 (6) Prinses Beatrix Fonds (W.OR11-27), PI, 2011 (7) Prinses Beatrix Spierfonds (W.OR12-04), PI, 2012 (8) Prinses Beatrix Spierfonds (W.OR14-04), Co-PI, 2014 (9) Prinses Beatrix Spierfonds (W.OR16-18), PI, 2016 (10) Prinses Beatrix Spierfonds (prof chair), PI, 2016-19 (11) Prinses Beatrix Spierfonds (W.OR19-24), PI, 2019

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Internal Medicine (M.Z., D.A.H., M.W.F.H., A.E.W.), Division of Nephrology and Transplantation; Rotterdam Transplant Group (M.Z., D.A.H., M.W.F.H., A.E.W.); Department of Neurology (E.B., P.A.D., B.C.J.); and Immunology (E.B., P.A.D., B.C.J.), Erasmus MC, University Medical Center Rotterdam, the Netherlands.
  1. Correspondence
    Dr. van der Zwan m.vanderzwan{at}erasmusmc.nl
View Full Text

Article usage

Article usage: April 2020 to June 2022

AbstractFullPdfSource
Apr 20202497103Highwire
May 2020420265Highwire
Jun 202035324Highwire
Jul 2020025731Highwire
Aug 202016911Highwire
Sep 2020513320Highwire
Oct 202046425Highwire
Nov 202015439Highwire
Dec 202013916Highwire
Jan 202173125Highwire
Feb 202103418Highwire
Mar 202123920Highwire
Apr 202132515Highwire
May 20214119Highwire
Jun 202152615Highwire
Jul 202112612Highwire
Aug 20214283Highwire
Sep 20212199Highwire
Oct 202112322Highwire
Nov 202104423Highwire
Dec 20210177Highwire
Jan 20221158Highwire
Feb 20222134Highwire
Mar 20220135Highwire
Apr 20220229Highwire
May 202232611Highwire
Jun 202231611Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

Topics Discussed

Alert Me

Advertisement